Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trimetrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA known ✓ | P00813 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimetrexate SCHEMBL6023395 | 0.87 | DHFR (0.40) | DHFRMEN1ALDH1A1ESR1CHRM2 | |
| Trimetrexate SCHEMBL19100456 | 0.84 | DHFR (0.59) | DHFRMEN1ALDH1A1ESR1CHRM2 | |
| Trimetrexate SCHEMBL4453809 | 0.81 | LMNA (0.41) | DHFRMEN1ALDH1A1ESR1CHRM2 | |
| Trimetrexate SCHEMBL5056582 | 0.74 | DHFR (0.60) | DHFRMEN1ALDH1A1ESR1CHRM2 | |
| Trimetrexate SCHEMBL27795867 | 0.73 | DHFR (0.90) | DHFRMEN1ALDH1A1ESR1CHRM2 | |
| Trimetrexate SCHEMBL29376841 | 0.72 | DHFR (1.00) | DHFRMEN1ALDH1A1ESR1CHRM2 | |
| Trimetrexate SCHEMBL3983 | 0.72 | DHFR (1.00) | DHFRMEN1ALDH1A1ESR1CHRM2 | |
| Trimetrexate SCHEMBL10701228 | 0.72 | DHFR (1.00) | DHFRMEN1ALDH1A1ESR1CHRM2 | |
| Trimetrexate SCHEMBL29403928 | 0.72 | DHFR (1.00) | DHFRMEN1ALDH1A1ESR1CHRM2 | |
| Pentostatin SCHEMBL7715689 | 0.72 | ADA (0.57) | PDE3AADRB1DNMT1ADAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375118-B2 | Phenyl-indole compounds for modulating IgE and Inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2008-05-20 | — | — | US | disclosed |
| US-7282518-B2 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | SIRCAR JAGADISH C | 2007-08-30 | — | — | US | disclosed |
| EP-1368028-B1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7256287-B2 | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1537079-A4 | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1494668-A4 | USE OF BENZIMIDAZOLE ANALOGS IN THE TREATMENT OF CELL PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1546157-A4 | PHENYL-AZA-BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-02-28 | — | — | EP | disclosed |
| CN-1826111-A | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS (US) | 2006-08-30 | — | — | CN | disclosed |
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040180946-A1 | Phenyl-indole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2004-09-16 | — | — | US | disclosed |
| US-6759425-B2 | USEFUL IN THE TREATMENT OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IGE IS PATHOGENIC; ALSO ARE USEFUL AS ANTICANCER AGENTS. | AVANIR PHARMACEUTICALS | 2004-07-06 | — | — | US | disclosed |
| US-20040116466-A1 | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2004-06-17 | — | — | US | disclosed |
| WO-2004024897-A2 | PHENYL-AZA-BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024896-A2 | PHENYL-INDOLE COMPOUNDS | AVANIR PHARMACEUTICALS (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1368028-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003082186-A2 | USE OF BENZIMIDAZOLE ANALOGS IN THE TREATMENT OF CELL PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002072090-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | MKI67, CMA1, CCNI | ADA 3837/4885DHFR 578/4885MEN1 4023/4885 |
| US-20040180946-A1 | Phenyl-indole compounds for modulating IgE and inhibiting cellular proliferation | IDO1, IDO2, CMA1 | ADA 4028/4885DHFR 723/4885MEN1 4414/4885 |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | MKI67, CMA1, CCNI | ADA 3837/4885DHFR 578/4885MEN1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.